TSC2 mutation
|
Peripheral T-cell Lymphoma
|
TSC2 mutation
|
Peripheral T-cell Lymphoma
|
copanlisib Sensitive: C3 – Early Trials
|
copanlisib Sensitive: C3 – Early Trials
|
TSC2 mutation
|
Endometrial Cancer
|
TSC2 mutation
|
Endometrial Cancer
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
TSC2 mutation
|
RCC
|
TSC2 mutation
|
RCC
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
TSC2 mutation
|
RCC
|
TSC2 mutation
|
RCC
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
TSC2 mutation
|
RCC
|
TSC2 mutation
|
RCC
|
mTOR inhibitor Sensitive: C3 – Early Trials
|
mTOR inhibitor Sensitive: C3 – Early Trials
|
TSC2 mutation
|
Pancreatic Cancer
|
TSC2 mutation
|
Pancreatic Cancer
|
Immunotherapy Sensitive: C4 – Case Studies
|
Immunotherapy Sensitive: C4 – Case Studies
|